Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control.
Authors
Woll, Penella JRanson, Malcolm R
Margison, Jennifer M
Thomson, Y
Van der Water, L
George, N
Howell, Anthony
Affiliation
CRC Department of Medical Oncology, Christie Hospital, Manchester, UK.Issue Date
1994-09
Metadata
Show full item recordAbstract
BACKGROUND: Suramin has shown promising activity against prostate and breast cancer but is severely neurotoxic. Complex adaptive pharmacokinetics have previously been used to adjust doses. We have undertaken a pilot study to assess the feasibility of administering suramin to outpatients with advanced cancer, using simple peak and trough monitoring. PATIENTS AND METHODS: Nine patients with cancer refractory to conventional therapy were studied, eight with breast cancer and one with prostate cancer. Two received continuous infusions of suramin 350 mg/m2/day through an indwelling central venous catheter. Both sustained axillary vein thromboses. Subsequent patients received suramin 500 mg/m2 as a one hour intravenous infusion thrice weekly until a trough serum level of 200 micrograms/ml was achieved. Treatment was repeated at 8 week intervals. Serum suramin levels were checked before and after each dose. RESULTS: Suramin treatment was well tolerated. Despite peak serum levels of up to 506 micrograms/ml, no serious toxicity was seen. No tumour responses were seen. CONCLUSIONS: We conclude that suramin can be safely and conveniently administered to outpatients by intermittent infusion without using complex adaptive dosing strategies. Suramin merits further study in less heavily pretreated breast cancer patients.Citation
Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control. 1994, 5 (7):597-600 Ann. Oncol.Journal
Annals of OncologyPubMed ID
7993834Type
ArticleLanguage
enISSN
0923-7534Collections
Related articles
- Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
- Authors: Kobayashi K, Vokes EE, Vogelzang NJ, Janish L, Soliven B, Ratain MJ
- Issue date: 1995 Sep
- Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
- Authors: Eisenberger MA, Reyno LM, Jodrell DI, Sinibaldi VJ, Tkaczuk KH, Sridhara R, Zuhowski EG, Lowitt MH, Jacobs SC, Egorin MJ
- Issue date: 1993 Apr 21
- Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
- Authors: Reyno LM, Egorin MJ, Eisenberger MA, Sinibaldi VJ, Zuhowski EG, Sridhara R
- Issue date: 1995 Sep
- Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
- Authors: Eisenberger MA, Sinibaldi VJ, Reyno LM, Sridhara R, Jodrell DI, Zuhowski EG, Tkaczuk KH, Lowitt MH, Hemady RK, Jacobs SC
- Issue date: 1995 Sep
- Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.
- Authors: Kelly WK, Scher HI, Mazumdar M, Pfister D, Curley T, Leibertz C, Cohen L, Vlamis V, Dnistrian A, Schwartz M
- Issue date: 1995 Sep